Erik A. Wist
Oslo, Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
A complex communication skills training program for physicians providing advanced cancer care - content development and barriers and solutions for implementation.
Journal: Journal of communication in healthcare
Published: March 15, 2023
The influence of metabolic factors and ethnicity on breast cancer risk, treatment and survival: The Oslo ethnic breast cancer study.
Journal: Acta oncologica (Stockholm, Sweden)
Published: March 29, 2022
Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER-positive breast cancer.
Journal: International journal of cancer
Published: November 01, 2019
Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations.
Journal: Genome medicine
Published: August 14, 2018
Metabolite and lipoprotein responses and prediction of weight gain during breast cancer treatment.
Journal: British journal of cancer
Published: January 14, 2018
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Journal: Breast cancer research and treatment
Published: September 18, 2017
Erratum: Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer.
Journal: NPJ breast cancer
Published: September 09, 2017
Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.
Journal: Breast cancer research : BCR
Published: June 21, 2017
Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013.
Journal: International journal of cancer
Published: March 21, 2017
The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 19, 2017
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Journal: The New England journal of medicine
Published: October 09, 2016
Last Updated: 09/26/2026